Kennealey G T, Boston B, Mitchell M S, Knobf M K, Bobrow S N, Pezzimenti J F, Lawrence R, Bertino J R
Cancer. 1978 Jul;42(1):27-33. doi: 10.1002/1097-0142(197807)42:1<27::aid-cncr2820420105>3.0.co;2-3.
Forty-eight women with advanced metastatic carcinoma of the breast were treated with one of two combination chemotherapy regimens: 1) adriamycin and cyclophosphamide or 2) adriamycin, cyclophosphamide, methotrexate and 5-fluorouracil. The response rate in the two-drug treatment group was 50% and in the four-drug treatment group, 55%. The median duration of response was ten months in both treatment groups. Dramatic responses were seen in patients with visceral metastases. Patients who responded to chemotherapy had a significantly longer survival than nonresponders (p less than 0.01). The long interval between adriamycin doses (six weeks) in the four drug regimen did not adversely effect the response rate--an important finding in view of the dose-related cardiac toxicity of this agent.
1）阿霉素和环磷酰胺；2）阿霉素、环磷酰胺、甲氨蝶呤和5-氟尿嘧啶。两药治疗组的缓解率为50%，四药治疗组为55%。两个治疗组的中位缓解持续时间均为十个月。在内脏转移患者中观察到显著缓解。对化疗有反应的患者的生存期明显长于无反应者（p<0.01）。四药方案中阿霉素剂量之间的长间隔（六周）并未对缓解率产生不利影响——鉴于该药物与剂量相关的心脏毒性，这是一个重要发现。
